Edwards Lifesciences has received the US Food and Drug Administration (FDA) approval for its SAPIEN M3 mitral valve replacement system.

At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from open-heart surgery to balloon valvuloplasty. What can I do to help the ...

Structural heart news arrived in a steady stream throughout 2025—from pivotal trials to approvals, reimbursement decisions, ...

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Severe valvular heart disease was not uncommon among patients with cancer, and intervention to manage the valvular disease ...

Q At age 51, I was diagnosed with severe rheumatic mitral stenosis. After a second round of tests, treatment was changed from ...

Irvine, California Friday, December 26, 2025, 11:00 Hrs [IST] ...

Routine echocardiography in cancer centers can spot severe valve disease earlier and trigger timely treatment decisions.

Edwards Lifesciences stock is supported by its growth outlook and the impact of clinical advances. See why investors should ...

The Sapien M3 transcatheter mitral valve replacement system won FDA approval -- making it the first on the market to utilize ...

By becoming the first health system in the region to offer robotic mitral valve surgery, this minimally invasive approach offers many benefits for patients. In this segment, cardiothoracic ...

Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, today announced ...